Navigation Links
Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
Date:10/18/2010

ug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep.  In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA.  In October 2010, Transcept announced preliminary results from the highway driving study of Intermezzo®.  Transcept plans to resubmit the Intermezzo® NDA in the first quarter of 2011, and anticipates a six-month review by the FDA. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Forward-looking statementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the following: plans and timing estimates to resubmit the Intermezzo® NDA and complete regulatory review with the FDA; the ability of Transcept to resubmit the Intermezzo® NDA with sufficient content to warrant FDA approval; the types of data and other information expect
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
2. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at BIO Investor Forum
4. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
7. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
8. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
10. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
11. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), ... repair and regeneration, today announced that J.J. Finkelstein ... present a corporate overview at two upcoming investor conferences. ... SeeThruEquity 4 th Annual Microcap Conference on Thursday ... at 11:00 am EDT.  A webcast will ...
(Date:5/22/2015)... , May 22, 2015  The Mesothelioma ... diagnosed victims of mesothelioma get the best possible ... certain individuals with this rare cancer caused by ... most up-to-date information related to treatment options such ... please call the Mesothelioma Victims Center anytime at ...
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 52015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... Topsfield, MA (PRWEB) May 22, 2015 ... Keri Hart, MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President ... International, “A very important ‘language’ that impacts how ... International, the leader in long term care reimbursement, ... and education programs and talent management, launches a ...
(Date:5/22/2015)... R.I. (PRWEB) May 22, 2015 Memorial Day ... Amica Insurance is offering some tips to help ... Safety Council, there will be 383 traffic fatalities this Memorial ... from the National Highway Traffic Safety Association: , ... in the vehicle is wearing a seatbelt, whether they’re driving ...
(Date:5/22/2015)... ZH Healthcare (ZH), ... today that Bill Lane, joins ZH’s Advisory Board. ... BlueEHS,a first of its kind, Freemium SaaS, Electronic ... Health Records (EHR) with an integrated practice management ... patient portal, and more. Combined with its Revenue ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... of colon cancer and colon polyps in men, a new ... of Seattle’s Fred Hutchinson Cancer Research Center studied 102 men ... half the participants were asked to exercise, while the rest ... Men who exercised showed less cancer-cell growth compared to men ...
... Studies show that 'Raloxifene' can reduce postmenopausal women with any ... that has been published in the September 1 issue of ... invasive breast cancer immaterial of whether they are at high ... study had also shown that the drug could reduce the ...
... disorder in human faculties" increases dependence on others and ... Wednesday urged researchers to "direct their efforts in bringing ... autism".// ,Equality can be generated by prevention, ... engaging the minds of affected children in productive efforts ...
... program developed by researchers now at the University of ... to study how individuals with sickle cell disease can ... ,The $2.9 million four-year study will ... Center at Chicago Comprehensive Sickle Cell Center by using ...
... said that it will undertake the subjects of brain tumors, ... changes that lead to cancer.// ,The agency has said ... hundreds or thousands of new genes involved in cancer, so ... treat it and tools to diagnose it. ,Acting director ...
... hearings by the Medical Council must be conducted in private, ... recent proposal that will mandate a public hearing in specific ... additional charge over appointments and control of the council. , ... giving the minister the power to appoint all 25 members ...
Cached Medicine News:Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3Health News:Autistic Children Need Sense of Equality: A.P.J. Abdul Kalam 2Health News:Computer May Improve Pain Relief for Sickle Cell Patients 2
... its great versatility in epilation and ... the compactness and easy-transportability of the ... protocols developed for Smartepil II plus, ... indicated for hair removal of tricky ...
... Plus is a CO2 laser system ... W. Its functions in continuous and ... requiring extreme laser intervention delicacy. Excellent ... studios, it comes with a large ...
... Performance ZyDoc offers HIPAA-secure web-based access to ... days a week through the utilization of ... documents, listen to the original dictation at ... electronically sign the document, and fax to ...
Auto Refkeratomoeter...
Medicine Products: